HOME >> BIOLOGY >> NEWS
Experimental Staph Vaccine Broadly Protective In Animal Studies

Researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID) have developed a vaccine that protects mice against multiple strains of Staphylococcus aureus (S. aureus), an increasingly stubborn microbe and the most common cause of hospital-acquired infections. The new vaccine is the first to be made from a bacterial molecule produced primarily during infection, rather than in laboratory culture. A report of the study by scientists at Brigham and Women's Hospital and Harvard Medical School in Boston appears in the May 28, 1999, issue of Science.

"This is an intriguing finding and a hopeful step against a very worrisome pathogen," says NIAID Director Anthony S. Fauci, M.D. "Within the last two years, S. aureus has become increasingly resistant to antibiotics. Most troubling is the emergence of strains that are partially resistant to vancomycin, our last line of defense against S. aureus. New treatments and, ideally, an effective vaccine, are urgently needed."

Each year an estimated 500,000 patients in American hospitals contract staph infections. S. aureus, the chief culprit, also is a common source of community acquired infections, and causes illnesses that range from minor skin infections and abscesses to life-threatening diseases such as severe pneumonia, meningitis, bone and joint infections, and infections of the heart and bloodstream.

Molecules isolated from bacteria grown in the laboratory have been one source of new vaccine candidates. However, since bacterial growth under laboratory conditions may not mimic an actual infection, scientists recently have begun searching for bacterial products that are activated specifically during infection.

"Presumably, these products are critical for infection and disease progression, and would therefore be logical targets for new therapeutics or vaccines," explains Gerald B. Pier, Ph.D., who led the research team that developed the new S. aureus vaccine.

The resear
'"/>

Contact: John Bowersox
jbowersox@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
28-May-1999


Page: 1 2 3

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental Biology 2003 meets in San Diego April 11-15
10. Experimental gene switch increases lifespan with no ill effects
11. Experimental therapy stops allergic reactions in mice

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... , ... August 25, 2020 , ... ... manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, ... Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – ...
(Date:8/21/2020)... (PRWEB) , ... August 19, 2020 , ... ... the premier conference and expo uniting life science, data science, informatics and IT ... sessions. , “In this period of uncertainty and change, Bio-IT takes the leadership ...
(Date:8/7/2020)... ... August 06, 2020 , ... Nine middle school teachers from ... Program, a unique professional development program that provides advanced STEM (science, technology, engineering ... teachers nationwide. , Created in partnership between the National Stem Cell Foundation and ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... ... announced today that Massachusetts Institute of Technology (MIT) has expanded the company’s ... allows PathSensors to move into the point-of-care diagnostic market, focusing initially on ...
(Date:7/10/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join ... Dr. Nissenson serves as an Emeritus Professor of Medicine at the David ...
(Date:7/7/2020)... ... July 06, 2020 , ... ... from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, ... has hosted an elite awards program, highlighting outstanding examples of how technology innovations ...
(Date:7/1/2020)... ... June 29, 2020 , ... The Interlocal Purchasing ... to its membership, recently named BioFit Engineered Products an Awarded Vendor. ... purchase ergonomic seating, cafeteria tables, book trucks and carts at discounted pricing without ...
Breaking Biology Technology:
Cached News: